苯达莫司汀联合化疗治疗复发难治性多发性骨髓瘤的疗效观察

Efficacy of Bendamustine combined with chemotherapy in the treatment of relapsed/refractory multiple myeloma.

目的观察苯达莫司汀联合化疗在复发难治性多发性骨髓瘤患者中的疗效及安全性。方法回顾性分析2020年5月至2021年1月在河南省肿瘤医院血液科收治的32例应用苯达莫司汀联合化疗的复发难治性多发性骨髓瘤(MM)患者的临床资料。结果32例复发难治性MM患者中31例可进行疗效评估,总体缓解率(ORR)为51.6%,其中完全缓解(CR)4例(12.9%),非常好的部分缓解(VGPR)3例(9.7%),部分缓解(PR)9例(29.0%)。前期接受三线及以上治疗的患者ORR明显低于接受一、二线治疗的。最常见的血液学和非血液学不良反应分别是是血小板降低(62.5%)和恶心、呕吐(56.3%),但给予对症治疗后,症状缓解,均未影响正常治疗进程。结论对于复发难治性多发性骨髓瘤患者,苯达莫司汀联合化疗可以作为一种安全可行的治疗方案。

Objective To observe the efficacy and safety of bendamustine combined with chemotherapy in patients with relapsed/refractory multiple myeloma.Methods Clinical data of 32 patients with relapsed/refractory multiple myeloma treated with bendamustine combined with chemotherapy in hematology department of Henan Cancer Hospital from May 2020to January 2021 were retrospectively analyzed.Results Thirty-one of the 32 patients with relapsed/refractory MM could be evaluated.The overall response rate(ORR)was 51.6%,including complete response(CR)in 4 cases(12.9%),very good partial response(VGPR)in 3 cases(9.7%),and partial response(PR)in 9 cases(29.0%).ORR was significantly lower in patients who received first-line or second-line treatment.The most common hematologic and non-hematologic adverse events were thrombocytopenia(62.5%)and nausea/vomiting(56.3%),respectively,which were relieved after symptomatic treatment and did not affect the normal course of treatment.Conclusion Bendamustine combined with chemotherapy is a safe and feasible treatment for patients with relapsed/refractory multiple myeloma.